Zobrazeno 1 - 10
of 54
pro vyhledávání: '"α1 blocker"'
Autor:
Ryszard Hanecki
Publikováno v:
Medycyna Faktów. 13:467-472
α1-blockers are a wide group of substances; there is possible to choose optimal α1-blocker therapy for various patients with lower urinary tract complaints. Since there is no one-size-fits-all drug, you should make the best use of the strengths of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6876deb9acfa7cffdec4f1954ea0e42a
https://doi.org/10.24292/01.mf.0420.13
https://doi.org/10.24292/01.mf.0420.13
Autor:
Watanabe, Masaki, Wada, Naoki, Kita, Masafumi, Hori, Junichi, Tamaki, Gaku, Kakizaki, Hidehiro
Publikováno v:
泌尿器科紀要. 66(9):289-292
We retrospectively investigated the clinical course of α1 blocker discontinuation in patients who had lower urinary tract symptoms with benign prostate hypertrophy (LUTS/BPH) and received combination therapy ofdutasteride and α1 blocker. Among the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::29093ad5283a09eca249338d43d734c2
http://hdl.handle.net/2433/255209
http://hdl.handle.net/2433/255209
Publikováno v:
Basrah Journal of Surgery, Vol 25, Iss 2, Pp 21-27 (2019)
The role of Tamsulosin in the treatment of ureteral stent related symptoms in Basrah General Hospital Firas Shakir Attar@, Adnan Odhafa Almayyahi# & Ibrahim Mahjar Tuama Flayyih* @MB,ChB, FIBMS, Assistant Professor at Basrah College of Medicine, Depa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69688c618fe211b65fc4b2c52e594360
https://bjsrg.uobasrah.edu.iq/article_164510_3b012e49d17df666b1ba30f75bb5f8df.pdf
https://bjsrg.uobasrah.edu.iq/article_164510_3b012e49d17df666b1ba30f75bb5f8df.pdf
Autor:
Christian G. Stief, Martin Hennenberg, Raphaela Waidelich, Alexander Tamalunas, Bingsheng Li, Ru Huang, Yuhan Liu, Frank Strittmatter, Ruixiao Wang
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Mirabegron inhibits detrusor smooth muscle contractions and is available for treatment of overactive bladder. Consequently, its effects on lower urinary tract symptoms (L...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6da79cd2c24300f2e5eac70d073f7f19
https://doi.org/10.1097/ju.0000000000001986.07
https://doi.org/10.1097/ju.0000000000001986.07
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology, Vol 11 (2020)
Objective To systematically evaluate the quality of clinical practice guidelines (CPG) for medically treating benign prostatic hyperplasia (BPH), and to compare the context of recommendations in order to provide references for clinical application. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c415ed5f228e584270a36495de3dfc8a
http://europepmc.org/articles/PMC7109311
http://europepmc.org/articles/PMC7109311
Publikováno v:
Офтальмохирургия, Vol 0, Iss 2, Pp 16-21 (2016)
Purpose. To determine prognostic criteria of clinically significant intra-operative floppy iris syndrome (IFIS) in patients receiving α1-blockers. Material and methods. Using the optical coherence tomography of the anterior segment of the eye (AS-OC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4377ca9dee7e07cd8c4d6a74f91f6d18
https://www.ophthalmosurgery.ru/jour/article/view/248
https://www.ophthalmosurgery.ru/jour/article/view/248
Publikováno v:
European Urology Supplements. 16:e938-e940
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37056d8ec955be21478fef57d61ff09b
https://doi.org/10.1016/s1569-9056(17)30601-2
https://doi.org/10.1016/s1569-9056(17)30601-2
Autor:
Sakata Koichi, Morita Tatsuo
Publikováno v:
BMC Urology, Vol 12, Iss 1, p 29 (2012)
Abstract Background To assess the ejaculatory disorder caused by silodosin in the prostatic hyperplasia patients who carry out sexual actions (sexual intercourse, masturbation). Method The subjects of this study were 91 patients who had been clinical
Externí odkaz:
https://doaj.org/article/d09fc74b031e45e7ac538ddddc67178e
Publikováno v:
International Journal of Basic & Clinical Pharmacology. 8:1248
Background: Fixed dose combination (FDC’s) of α1-blockers and 5α-reductase inhibitors have commonly been used in patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). This study compared the effect of FDC’s o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::124d04f0ca05e16c000dba1992cf66d7
https://doi.org/10.18203/2319-2003.ijbcp20192184
https://doi.org/10.18203/2319-2003.ijbcp20192184
Autor:
H.-C. Yeh, Chun Nung Huang, Chia-Chu Liu, Chun Hsiung Huang, Wei-Ming Li, W.-J. Wu, Yung-Shun Juan, Yung-Chin Lee, Shu Pin Huang, Chii-Jye Wang
Publikováno v:
International Journal of Clinical Practice. 67:356-362
Summary Aims: Increasing evidence has proposed the components of metabolic syndrome (MtS) as risk factors for the development of benign prostate hyperplasia (BPH); therefore, it is thought that MtS may play a role in lower urinary tract symptoms rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a8ba7a4fc287b3fd5659f0a1ffa583e
https://doi.org/10.1111/ijcp.12086
https://doi.org/10.1111/ijcp.12086